Literature DB >> 18303390

Effect of flunarizine, a calcium channel blocker, on intraocular pressure and aqueous humor dynamics in monkeys.

Rong-Fang Wang1, Donna J Gagliuso, Steven M Podos.   

Abstract

PURPOSE: To evaluate the effects of flunarizine, a nonselective calcium channel blocker, on intraocular pressure (IOP) in monkeys with laser-induced unilateral glaucoma and on aqueous humor dynamics in normal monkeys.
METHODS: The IOP was measured before and hourly for 6 hours after single-dose administration of 0.5%, 1%, or 2% flunarizine to the glaucomatous eye of 8 monkeys with unilateral laser-induced glaucoma. In a separate multiple-dose study, 0.5% flunarizine was applied twice daily for 5 consecutive days to the glaucomatous eye of the same 8 monkeys. IOP was measured at untreated baseline, after treatment with vehicle only, and on treatment days 1, 3, and 5. Tonographic outflow facility and fluorophotometric flow rates of aqueous humor were measured in 7 normal monkeys before and after the fifth dose of twice-daily treatment with 0.5% flunarizine.
RESULTS: Unilateral application of 50 microL of 0.5%, 1%, or 2% flunarizine reduced IOP bilaterally. In the treated glaucomatous eyes, flunarizine reduced the IOP for 2, 3, or 5 hours, with a maximum reduction of 2.5+/-0.5 (mean+/-SEM) mm Hg (9%), 3.0+/-0.4 mm Hg (10%), and 5.0+/-0.8 mm Hg (18%) following the 0.5%, 1%, and 2% concentrations, respectively (P<0.01). The maximum reductions in IOP in the contralateral untreated eyes were 1.3+/-0.5 mm Hg, 1.5+/-0.3 mm Hg, and 2.9+/-0.7 mm Hg following the 0.5%, 1%, and 2% concentrations, respectively (P<0.05). Both the magnitude and duration of the ocular hypotensive effect of 0.5% flunarizine were enhanced with twice-daily administration for 5 days. Outflow facility in normal monkey eyes was increased (P<0.05) by 39% in the treated eyes compared with vehicle-treated contralateral eyes and by 41% compared with baseline values, and aqueous humor flow rates were unchanged (P>0.30).
CONCLUSIONS: Flunarizine reduces IOP in a dose-dependent manner when administered to glaucomatous monkey eyes, but also has an ocular hypotensive effect on the contralateral untreated eyes. An increase in tonographic outflow facility seems to account for the IOP reduction in normal monkey eyes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18303390     DOI: 10.1097/IJG.0b013e318133a845

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  6 in total

1.  TRPC6: an underlying target for human glaucoma.

Authors:  Qian Fan; Wen-Bin Huang; Xiu-Lan Zhang
Journal:  Int J Ophthalmol       Date:  2012-08-18       Impact factor: 1.779

2.  1α,25-Dihydroxyvitamin D(3) and its analog, 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D(3) (2MD), suppress intraocular pressure in non-human primates.

Authors:  Galina D Kutuzova; B'ann T Gabelt; Julie A Kiland; Elizabeth A Hennes-Beann; Paul L Kaufman; Hector F DeLuca
Journal:  Arch Biochem Biophys       Date:  2011-12-16       Impact factor: 4.013

3.  Mitochondrial dependent apoptosis: ameliorative effect of flunarizine on ischemia-reperfusion of celiac artery-induced gastric lesions in the rat.

Authors:  Arunachalam Muthuraman; Muthusamy Ramesh; Ashish Chauhan
Journal:  Dig Dis Sci       Date:  2011-02-16       Impact factor: 3.199

Review 4.  Discovery of novel inhibitors for the treatment of glaucoma.

Authors:  Kishore Cholkar; Hoang M Trinh; Dhananjay Pal; Ashim K Mitra
Journal:  Expert Opin Drug Discov       Date:  2015-01-09       Impact factor: 6.098

5.  Glutamate-induced internalization of Ca(v)1.3 L-type Ca(2+) channels protects retinal neurons against excitotoxicity.

Authors:  Fengxia Mizuno; Peter Barabas; David Krizaj; Abram Akopian
Journal:  J Physiol       Date:  2010-02-01       Impact factor: 5.182

Review 6.  Influence of Trace Elements on Neurodegenerative Diseases of The Eye-The Glaucoma Model.

Authors:  Agnieszka Kamińska; Giovanni Luca Romano; Robert Rejdak; Sandrine Zweifel; Michal Fiedorowicz; Magdalena Rejdak; Anahita Bajka; Rosario Amato; Claudio Bucolo; Teresio Avitabile; Filippo Drago; Mario Damiano Toro
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.